67 related articles for article (PubMed ID: 30926087)
1. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
Xu QY; Yu L
Chin Med J (Engl); 2020 Mar; 133(6):699-715. PubMed ID: 32044818
[TBL] [Abstract][Full Text] [Related]
2. The DNA methylation landscape across the TCR loci in patients with acute myeloid leukemia.
Pospiech M; Beckford J; Kumar AMS; Tamizharasan M; Brito J; Liang G; Mangul S; Alachkar H
Int Immunopharmacol; 2024 Jun; 138():112376. PubMed ID: 38917523
[TBL] [Abstract][Full Text] [Related]
3. Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy.
Campillo-Marcos I; Casado-Pelaez M; Davalos V; Ferrer G; Mata C; Mereu E; Roué G; Valcárcel D; Molero A; Zamora L; Xicoy B; Palomo L; Acha P; Manzanares A; Tobiasson M; Hellström-Lindberg E; Solé F; Esteller M
Cancer Res Commun; 2024 Feb; 4(2):365-377. PubMed ID: 38300528
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia.
Humphries S; Bond DR; Germon ZP; Keely S; Enjeti AK; Dun MD; Lee HJ
Clin Epigenetics; 2023 Sep; 15(1):150. PubMed ID: 37705055
[TBL] [Abstract][Full Text] [Related]
5. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Croucher PJP; Ridinger M; Becker PS; Lin TL; Silberman SL; Wang ES; Zeidan AM
Ann Hematol; 2023 Nov; 102(11):3049-3059. PubMed ID: 37702821
[TBL] [Abstract][Full Text] [Related]
6. A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data.
Sharplin K; Proudman W; Chhetri R; Tran ENH; Choong J; Kutyna M; Selby P; Sapio A; Friel O; Khanna S; Singhal D; Damin M; Ross D; Yeung D; Thomas D; Kok CH; Hiwase D
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627047
[TBL] [Abstract][Full Text] [Related]
7. In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts.
Greve G; Andrieux G; Schlosser P; Blagitko-Dorfs N; Rehman UU; Ma T; Pfeifer D; Heil G; Neubauer A; Krauter J; Heuser M; Salih HR; Döhner K; Döhner H; Hackanson B; Boerries M; Lübbert M
Leukemia; 2023 May; 37(5):1018-1027. PubMed ID: 37024521
[TBL] [Abstract][Full Text] [Related]
8. A machine learning model of response to hypomethylating agents in myelodysplastic syndromes.
Radakovich N; Sallman DA; Buckstein R; Brunner A; Dezern A; Mukerjee S; Komrokji R; Al-Ali N; Shreve J; Rouphail Y; Parmentier A; Mamedov A; Siddiqui M; Guan Y; Kuzmanovic T; Hasipek M; Jha B; Maciejewski JP; Sekeres MA; Nazha A
iScience; 2022 Oct; 25(10):104931. PubMed ID: 36157589
[TBL] [Abstract][Full Text] [Related]
9. Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes.
Kim S; Shin DY; Kim D; Oh S; Hong J; Kim I; Kim E
Cells; 2021 Dec; 10(12):. PubMed ID: 34944006
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia.
Santini V; Lübbert M; Wierzbowska A; Ossenkoppele GJ
Adv Ther; 2022 Apr; 39(4):1474-1488. PubMed ID: 34786648
[TBL] [Abstract][Full Text] [Related]
11. 5-Aza-4'-thio-2'-deoxycytidine, a New Orally Bioavailable Nontoxic "Best-in-Class": DNA Methyltransferase 1-Depleting Agent in Clinical Development.
Parker WB; Thottassery JV
J Pharmacol Exp Ther; 2021 Nov; 379(3):211-222. PubMed ID: 34503994
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.
Stomper J; Rotondo JC; Greve G; Lübbert M
Leukemia; 2021 Jul; 35(7):1873-1889. PubMed ID: 33958699
[TBL] [Abstract][Full Text] [Related]
13. Can we predict responsiveness to hypomethylating agents in AML?
Stomper J; Lübbert M
Semin Hematol; 2019 Apr; 56(2):118-124. PubMed ID: 30926087
[TBL] [Abstract][Full Text] [Related]
14. Decitabine Induces Gene Derepression on Monosomic Chromosomes:
Greve G; Schüler J; Grüning BA; Berberich B; Stomper J; Zimmer D; Gutenkunst L; Bönisch U; Meier R; Blagitko-Dorfs N; Grishina O; Pfeifer D; Weichenhan D; Plass C; Lübbert M
Cancer Res; 2021 Feb; 81(4):834-846. PubMed ID: 33203699
[TBL] [Abstract][Full Text] [Related]
15. [Markers for Predicting Response to Hypomethylating Agents in MDS and AML Patients].
Chen XP; Jing Y; Li YH; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1769-73. PubMed ID: 26708908
[TBL] [Abstract][Full Text] [Related]
16. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
17. How Epigenetic Therapy Beats Adverse Genetics in Monosomy Karyotype AML.
O'Hagan HM; Rassool FV; Nephew KP
Cancer Res; 2021 Feb; 81(4):813-815. PubMed ID: 33822747
[TBL] [Abstract][Full Text] [Related]
18. Hypomethylating Agents as a Therapy for AML.
Gardin C; Dombret H
Curr Hematol Malig Rep; 2017 Feb; 12(1):1-10. PubMed ID: 28286907
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
